双相障碍与精神分裂症中多巴胺合成能力的跨诊断检测
该横断面病例对照PET研究纳入22例伴精神病性症状的双相障碍患者、16例精神分裂症患者和22名匹配对照,发现两组患者纹状体多巴胺合成能力均高于对照,且与阳性精神病性症状严重度正相关,支持精神病性障碍的多巴胺功能异常具有跨诊断作用。
要点
- 伴精神病性症状的双相障碍患者纹状体多巴胺合成能力显著高于对照。
- 双相障碍与精神分裂症患者间纹状体多巴胺合成能力无显著差异。
- 多巴胺合成能力与阳性精神病性症状严重度正相关,双相障碍中独立于躁狂症状。
核心结论
- 研究结果支持多巴胺功能异常在精神病性障碍病理病因学中具有跨诊断作用。
- 多巴胺合成能力可能是双相障碍和精神分裂症的潜在新药靶点。
研究设计与样本
- 共60名参与者:22例伴精神病性症状的双相障碍患者(18例未用或停用抗精神病药)、16例精神分裂症患者(14例未用或停用抗精神病药)和22名匹配对照。
- 所有参与者接受[18F]-DOPA PET检查以评估多巴胺合成能力,并完成阳性与阴性症状量表、年轻躁狂评定量表和功能总体评估等标准化临床测量。
主要发现
- 纹状体多巴胺合成能力(Kicer)存在显著组间差异(F2,57=6.80,P=.002)。
- 双相障碍组Kicer均值(SD)为13.18(1.08)×10^-3 min^-1,显著高于对照组12.16(0.92)×10^-3 min^-1(P=.002)。
- 精神分裂症组Kicer均值(SD)为12.94(0.79)×10^-3 min^-1,显著高于对照组(P=.04)。
- 双相障碍组与精神分裂症组间纹状体Kicer无显著差异。
- 在合并双相障碍和精神分裂症且当前处于精神病性发作的样本中,Kicer与阳性精神病性症状严重度显著正相关,解释症状严重度27%的变异(n=32,r=0.52,P=.003)。
临床怎么用
- 对于伴精神病性症状的双相障碍和精神分裂症患者,纹状体多巴胺合成能力升高可作为跨诊断的生物学特征加以评估。
- 多巴胺合成能力与阳性精神病性症状严重度相关,提示其可能用于辅助评估症状维度而非仅凭诊断分类。
- 多巴胺合成能力作为潜在新药靶点,提示针对多巴胺通路干预可能对双相障碍和精神分裂症均有益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The dopamine hypothesis suggests that dopamine abnormalities underlie psychosis, irrespective of diagnosis, implicating dopamine dysregulation in bipolar affective disorder and schizophrenia, in line with the research domain criteria approach. However, this hypothesis has not been directly examined in individuals diagnosed with bipolar disorder with psychosis. OBJECTIVES: To test whether dopamine synthesis capacity is elevated in bipolar disorder with psychosis and how this compares with schizophrenia and matched controls and to examine whether dopamine synthesis capacity is associated with psychotic symptom severity, irrespective of diagnostic class. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional case-control positron emission tomographic study was performed in the setting of first-episode psychosis services in an inner-city area (London, England). Sixty individuals participated in the study (22 with bipolar psychosis [18 antipsychotic naive or free], 16 with schizophrenia [14 antipsychotic naive or free], and 22 matched controls) and underwent fluorodihydroxyphenyl-l-alanine ([18F]-DOPA) positron emission tomography to examine dopamine synthesis capacity. Standardized clinical measures, including the Positive and Negative Syndrome Scale, Young Mania Rating Scale, and Global Assessment of Functioning, were administered. The study dates were March 2013 to November 2016. MAIN OUTCOMES AND MEASURES: Dopamine synthesis capacity (Kicer) and clinical measures (Positive and Negative Syndrome Scale, Young Mania Rating Scale, and Global Assessment of Functioning). RESULTS: The mean (SD) ages of participants were 23.6 (3.6) years in 22 individuals with bipolar psychosis (13 male), 26.3 (4.4) years in 16 individuals with schizophrenia (14 male), and 24.5 (4.5) years in controls (14 male). There was a significant group difference in striatal dopamine synthesis capacity (Kicer) (F2,57 = 6.80, P = .002). Kicer was significantly elevated in both the bipolar group (mean [SD], 13.18 [1.08] × 10-3 min-1; P = .002) and the schizophrenia group (mean [SD], 12.94 [0.79] × 10-3 min-1; P = .04) compared with controls (mean [SD], 12.16 [0.92] × 10-3 min-1). There was no significant difference in striatal Kicer between the bipolar and schizophrenia groups. Kicer was significantly positively correlated with positive psychotic symptom severity in the combined bipolar and schizophrenia sample experiencing a current psychotic episode, explaining 27% of the variance in symptom severity (n = 32, r = 0.52, P = .003). There was a significant positive association between Kicer and positive psychotic symptom severity in individuals with bipolar disorder experiencing a current psychotic episode (n = 16, r = 0.60, P = .01), which remained significant after adjusting for manic symptom severity. CONCLUSIONS AND RELEVANCE: These findings are consistent with a transdiagnostic role for dopamine dysfunction in the pathoetiology of psychosis and suggest dopamine synthesis capacity as a potential novel drug target for bipolar disorder and schizophrenia.
引用
- Jauhar S, Nour MM, Veronese M, et al. A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. JAMA Psychiatry. 2017. PMID: 29049482. doi:10.1001/jamapsychiatry.2017.2943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。